Match!
Camilla Restellini
European Institute of Oncology
4Publications
1H-index
4Citations
Publications 4
Newest
#1Roberta Noberini (IEO: European Institute of Oncology)H-Index: 15
#2Camilla Restellini (IEO: European Institute of Oncology)H-Index: 1
Last.Tiziana Bonaldi (IEO: European Institute of Oncology)H-Index: 32
view all 4 authors...
Abstract Aberrations in histone post-translational modifications (PTMs) have been implicated with the development of numerous pathologies, including cancer. Therefore, profiling histone PTMs in patient samples could provide information useful for the identification of epigenetic biomarkers, as well as the discovery of potential novel targets. While antibody-based methods have been traditionally employed to analyze histone PTM in clinical samples, mass spectrometry (MS) can provide a more compreh...
Source
#1Laura De Clerck (UGent: Ghent University)H-Index: 4
#2Sander Willems (UGent: Ghent University)H-Index: 5
Last.Maarten Dhaenens (UGent: Ghent University)H-Index: 14
view all 9 authors...
Mass spectrometry (MS) has become the technique of choice for large-scale analysis of histone post-translational modifications (hPTMs) and their combinatorial patterns, especially in untargeted settings where novel discovery-driven hypotheses are being generated. However, MS-based histone analysis requires a distinct sample preparation, acquisition, and data analysis workflow when compared to traditional MS-based approaches. To this end, sequential window acquisition of all theoretical fragment ...
1 CitationsSource
#1Roberta NoberiniH-Index: 15
#2Camilla RestelliniH-Index: 1
Last.Tiziana BonaldiH-Index: 32
view all 18 authors...
Aberrations in histone post-translational modifications (PTMs), as well as in the histone modifying enzymes (HMEs) that catalyze their deposition and removal, have been reported in many tumors and many epigenetic inhibitors are currently under investigation for cancer treatment. Therefore, profiling epigenetic features in cancer could have important implications for the discovery of both biomarkers for patient stratification and novel epigenetic targets. In this study, we employed mass spectrome...
1 CitationsSource
#1Camilla Restellini (IEO: European Institute of Oncology)H-Index: 1
#2Alessandro Cuomo (IEO: European Institute of Oncology)H-Index: 15
Last.Roberta Noberini (IEO: European Institute of Oncology)H-Index: 15
view all 6 authors...
3 CitationsSource
1